Study of FT538 in Combination With Daratumumab in Acute Myeloid Leukemia
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Daratumumab/hyaluronidase (Primary) ; FT 538 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 12 Dec 2023 Results (n=6) assessing safety and efficacy were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 22 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2022 According to a Fate Therapeutics media release, the company is currently enrolling patients in the fourth multi-dose escalation cohort (1.5 billion cells per dose)